WTX-518 / Werewolf Therap - LARVOL DELTA

Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models (AACR 2024) - "WTX-518 is also selectively inducible, as incubation ex vivo with various primary human tumors led to the release of active BPR IL-18, while WTX-518 was stable in human serum and after exposure to primary cells from healthy tissues. Pharmacological and efficacy data support continued preclinical development of this innovative and differentiated engineered IL-18 therapy."

Preclinical • Tumor microenvironment • Oncology • CD4 • CD8 • IL18

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook (GlobeNewswire) - "Preclinical Portfolio: includes development candidates WTX-712 and WTX-518, our IL-21 and binding protein resistant IL-18 INDUKINE molecules, respectively, for treatment of cancer...In 2025, Werewolf plans to complete ongoing pre-clinical work to support IND-stage programs and seek strategic partnerships to advance these programs."

Preclinical • Oncology • Solid Tumor

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting (GlobeNewswire) - "Results highlighting WTX-518 findings are summarized in a poster titled, 'Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models' (Abstract #4074). Key takeaways reveal that WTX-518: is inducible, and its in vitro activity is not impeded by IL-18BP; selectively delivers active binding protein resistant (BPR) IL-18 to the tumor microenvironment (TME); and promotes increased influx and activation of NK cells and polyfunctional CD8 T cells in the TME, and demonstrates complete tumor regression in the MC38 mouse tumor model."

Preclinical • Oncology

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) - "In the first half of this year, we plan to present additional clinical data from our Phase 1/1b clinical trial of WTX-124, including updated monotherapy data and initial combination data, which we anticipate will build on the promising signals of antitumor activity and improved therapeutic index that we observed in the data presented at SITC last year. In addition, we plan to share data further demonstrating the performance of our platform in our preclinical programs at AACR. We also plan to share initial clinical data from WTX-330, our second clinical candidate, in the second quarter of 2024."

P1 data • Preclinical • Non-Hodgkin’s Lymphoma • Solid Tumor

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024 (GlobeNewswire) - "Werewolf Therapeutics...announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California."

Preclinical • Oncology

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook (GlobeNewswire) - "In 2024, Werewolf plans to: Present preclinical data from WTX-712 in the first half of 2024; Present preclinical data from WTX-518 in the first half of 2024."

Preclinical • Oncology